Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Seminars in Ophthalmology Pub Date : 2024-11-01 Epub Date: 2024-01-25 DOI:10.1080/08820538.2024.2308808

Srishti Raksheeth Ramamurthy, Umesh Chandra Behera, Ritesh Narula, SriniVas R Sadda, Raja Narayanan

{"title":"Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study.","authors":"Srishti Raksheeth Ramamurthy, Umesh Chandra Behera, Ritesh Narula, SriniVas R Sadda, Raja Narayanan","doi":"10.1080/08820538.2024.2308808","DOIUrl":null,"url":null,"abstract":"Purpose: To study intravitreal brolucizumab in the management of persistent macular fluid in chronic central serous chorioretinopathy (CSCR) without choroidal neovascular membrane (CNVM).Methods: Retrospective case series which included eyes with chronic CSCR with persistent macular fluid for ≥ 3 months without CNVM. Intravitreal brolucizumab was administered in all eyes. Primary outcome measure was the resolution of intraretinal (IRF) and/or subretinal fluid (SRF) on OCT.Results: Five eyes (four patients) with chronic CSCR were included. All eyes showed complete resolution of SRF 1 month following injection. Minimal residual IRF was present in two eyes. Best corrected visual acuity (BCVA) was stable in three eyes, and two eyes showed improvement. Central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) showed reduction.Conclusion: Intravitreal brolucizumab is effective in the rapid reduction of persistent macular fluid in chronic CSCR without CNVM. Long-term follow-up data are required to study recurrence and adverse effect profile.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"615-622"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2024.2308808","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To study intravitreal brolucizumab in the management of persistent macular fluid in chronic central serous chorioretinopathy (CSCR) without choroidal neovascular membrane (CNVM).

Methods: Retrospective case series which included eyes with chronic CSCR with persistent macular fluid for ≥ 3 months without CNVM. Intravitreal brolucizumab was administered in all eyes. Primary outcome measure was the resolution of intraretinal (IRF) and/or subretinal fluid (SRF) on OCT.

Results: Five eyes (four patients) with chronic CSCR were included. All eyes showed complete resolution of SRF 1 month following injection. Minimal residual IRF was present in two eyes. Best corrected visual acuity (BCVA) was stable in three eyes, and two eyes showed improvement. Central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) showed reduction.

Conclusion: Intravitreal brolucizumab is effective in the rapid reduction of persistent macular fluid in chronic CSCR without CNVM. Long-term follow-up data are required to study recurrence and adverse effect profile.

查看原文本刊更多论文

无脉络膜新生血管膜的慢性中心性浆液性脉络膜视网膜病变的玻璃体内布卢单抗--一项试验性研究。

目的：研究玻璃体内布鲁珠单抗治疗无脉络膜新生血管膜（CNVM）的慢性中心性浆液性脉络膜视网膜病变（CSCR）持续性黄斑积液的方法：方法：回顾性病例系列，包括持续黄斑积液≥3个月且无脉络膜新生血管膜的慢性中央型浆液性脉络膜视网膜病变患者。所有眼球均接受了玻璃体内注射肉毒杆菌。主要结果指标为 OCT 上视网膜内积液（IRF）和/或视网膜下积液（SRF）的消退情况：结果：共纳入五只患有慢性 CSCR 的眼睛（四名患者）。注射后 1 个月，所有患者的 SRF 均完全消退。两只眼睛存在轻微的残留 IRF。三只眼的最佳矫正视力（BCVA）保持稳定，两只眼有所改善。黄斑中心厚度（CMT）和眼底脉络膜厚度（SFCT）均有所下降：结论：对于无 CNVM 的慢性 CSCR，玻璃体内注射肉毒杆菌能有效快速减少持续性黄斑积液。需要长期随访数据来研究复发和不良反应情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Ophthalmology offers current, clinically oriented reviews on the diagnosis and treatment of ophthalmic disorders. Each issue focuses on a single topic, with a primary emphasis on appropriate surgical techniques.